Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H14N5O4P |
Molecular Weight | 299.223 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC=C2N=CN(CC3(CC3)OCP(O)(O)=O)C2=N1
InChI
InChIKey=KDNSSKPZBDNJDF-UHFFFAOYSA-N
InChI=1S/C10H14N5O4P/c11-9-12-3-7-8(14-9)15(5-13-7)4-10(1-2-10)19-6-20(16,17)18/h3,5H,1-2,4,6H2,(H2,11,12,14)(H2,16,17,18)
Molecular Formula | C10H14N5O4P |
Molecular Weight | 299.223 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
A novel class of phosphonate nucleosides. 9-[(1-phosphonomethoxycyclopropyl)methyl]guanine as a potent and selective anti-HBV agent. | 2004 May 20 |
|
Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. | 2010 Mar |
|
Pharmacokinetic comparison of the maleate and free base formulations of LB80380, a novel nucleotide analog, in healthy male volunteers. | 2012 Sep |
|
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. | 2014 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01937806
Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 20:14:59 GMT 2023
by
admin
on
Fri Dec 15 20:14:59 GMT 2023
|
Record UNII |
4PLG22CQUU
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5270766
Created by
admin on Fri Dec 15 20:14:59 GMT 2023 , Edited by admin on Fri Dec 15 20:14:59 GMT 2023
|
PRIMARY | |||
|
Besifovir
Created by
admin on Fri Dec 15 20:14:59 GMT 2023 , Edited by admin on Fri Dec 15 20:14:59 GMT 2023
|
PRIMARY | |||
|
300000036882
Created by
admin on Fri Dec 15 20:14:59 GMT 2023 , Edited by admin on Fri Dec 15 20:14:59 GMT 2023
|
PRIMARY | |||
|
9478
Created by
admin on Fri Dec 15 20:14:59 GMT 2023 , Edited by admin on Fri Dec 15 20:14:59 GMT 2023
|
PRIMARY | |||
|
441785-25-7
Created by
admin on Fri Dec 15 20:14:59 GMT 2023 , Edited by admin on Fri Dec 15 20:14:59 GMT 2023
|
PRIMARY | |||
|
4PLG22CQUU
Created by
admin on Fri Dec 15 20:14:59 GMT 2023 , Edited by admin on Fri Dec 15 20:14:59 GMT 2023
|
PRIMARY | |||
|
C166775
Created by
admin on Fri Dec 15 20:14:59 GMT 2023 , Edited by admin on Fri Dec 15 20:14:59 GMT 2023
|
PRIMARY | |||
|
DB15671
Created by
admin on Fri Dec 15 20:14:59 GMT 2023 , Edited by admin on Fri Dec 15 20:14:59 GMT 2023
|
PRIMARY | |||
|
DTXSID601027760
Created by
admin on Fri Dec 15 20:14:59 GMT 2023 , Edited by admin on Fri Dec 15 20:14:59 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|